Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014

@inproceedings{Cazanave2015SwitchTR,
  title={Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les H{\'e}patites Virales CO3 Aquitaine Cohort, 2012–2014},
  author={Charles Cazanave and Sandrine Reigadas and Cyril Mazubert and Pantxika Bellecave and Mojgan Hessamfar and Fabien le Marec and E Quintanilla L{\'a}zaro and Gilles Peytavin and Mathias Bruyand and H{\'e}rv{\'e} Fleury and François Dabis and Didier Neau},
  booktitle={Open forum infectious diseases},
  year={2015}
}
Background.  The purpose of this study was to assess the efficacy and tolerability of combined antiretroviral therapy (cART) in human immunodeficiency virus (HIV)-1 virologically suppressed patients who switched to rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) as a single-tablet regimen (STR). Methods.  A retrospective multicenter cohort study was performed between September 2012 and February 2014 in Bordeaux University Hospital-affiliated clinics. Patients with a… CONTINUE READING